The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome

Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly pop...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Amanda McBride, Sarah Houtmann, Lindsay Wilde, Carlos Vigil, Christine M. Eischen, Margaret Kasner, Neil Palmisiano
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-03-01
Subjects:	BCL-2 venetoclax AML ALL MDS intrinsic apoptosis
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2019.00192/full

Similar Items

Fixed-time treatment of elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) using hypomethylating agents and venetoclax – a case series
by: Albrecht Lindemann, et al.
Published: (2026-05-01)

Bcl-2 inhibition in the treatment of hematologic malignancies
by: John X. Wei, et al.
Published: (2023-12-01)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
by: Tianming Zhao, et al.
Published: (2023-01-01)

Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
by: Yunxiong Wei, et al.
Published: (2020-12-01)

BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
by: Jing-dong Zhou, et al.
Published: (2019-06-01)

Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes
by: Kevin Yao, et al.
Published: (2023-03-01)

The role of RAS mutations in leukemia progression, differentiation, and drug resistance
by: Congfa Jiang, et al.
Published: (2026-01-01)

Targeting the Bcl-2 Family in B Cell Lymphoma
by: Clare M. Adams, et al.
Published: (2019-01-01)

Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab
by: Fadi Haddad, et al.
Published: (2021-05-01)

Case report: Dynamic genetic profiles reveal a patient with myelodysplastic neoplasm transforming into acute myeloid leukemia
by: Guiying Guo, et al.
Published: (2026-03-01)

Acute myeloid leukemia cells and MSC-derived exosomes inhibiting transformation in myelodysplastic syndrome
by: Xiaoli Liu, et al.
Published: (2023-06-01)

CLINICAL AND CYTOGENETIC PROFILE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
by: Muneshwar Kumar, et al.
Published: (2019-06-01)

Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management
by: Laura Giuseppina Di Pasqua, et al.
Published: (2024-04-01)

Abivertinib synergistically strengthens the anti‐leukemia activity of venetoclax in acute myeloid leukemia in a BTK‐dependent manner
by: Shujuan Huang, et al.
Published: (2020-10-01)

Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia
by: Lixian Chang, et al.
Published: (2023-11-01)

The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID
by: Antonio Cristiano, et al.
Published: (2022-04-01)

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy
by: Mustafa Nissar Bankur, et al.
Published: (2022-06-01)

Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy
by: Qiao Zhou, et al.
Published: (2024-01-01)

Flow Cytometry Analysis of Mesenchymal Stem Cells: A Predictive Biomarker for Leukemia Transformation in Myelodysplastic Syndrome
by: Mireia Atance, et al.
Published: (2025-06-01)

The Role of BCL-2 Expression in Patients with Myelodysplastic Neoplasms
by: Bartłomiej Kuszczak, et al.
Published: (2025-05-01)

Venetoclax–azacitidine as a bridge to transplant in pediatric relapsed/refractory acute myeloid leukemia: A real-world experience
by: Sunisha Arora, et al.
Published: (2026-06-01)

Combination Treatment of Resistant Acute Promyelocytic Leukemia Cells with Arsenic Trioxide and Anti-Apoptotic Gene Inhibitors
by: Manuela Giansanti, et al.
Published: (2024-11-01)

Influence of different therapy strategies in patients with myelodysplastic neoplasms (MDS) on overall survival with regard to different decades: data from the German MDS registry
by: Jonas Welsch, et al.
Published: (2026-04-01)

Advances in the role of the IGF signaling system in myelodysplastic syndromes and acute myeloid leukemia
by: Yifan Wang, et al.
Published: (2025-06-01)

Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
by: Kulsoom B, et al.
Published: (2018-03-01)

Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling
by: Lin Chen, et al.
Published: (2023-09-01)

Venetoclax in T-cell Acute Lymphoblastic Leukemia: The Impact of BCL-2 Inhibition on Treatment Efficacy
by: Kaveh Tari, et al.
Published: (2023-11-01)

HAPLOIDENTICAL TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS: THE ROLE OF PREVIOUS LINES OF THERAPY.
by: Daniele Avenoso, et al.
Published: (2024-01-01)

Correlation between Bcl-2 Expression and the Efficacy of Bcl-2 Inhibitors in Patients with Myelodysplastic Syndromes
by: WU Jiafei, WANG Jun, WANG Yijing, ZHENG Boyue, WANG Yu, JIANG Chuanyan, DONG Dandan, LI Hui
Published: (2024-06-01)

High <i>BECN1</i> Expression Negatively Correlates with <i>BCL2</i> Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy
by: Amreen Salwa, et al.
Published: (2023-07-01)

The role of the CLL-1 protein in disease monitoring in patients diagnosed with acute myeloid leukaemia and myelodysplastic syndrome
by: Ewa Dobak, et al.
Published: (2024-10-01)

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine
by: Hiroshi Handa, et al.
Published: (2022-05-01)

Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression
by: Scott Auerbach, et al.
Published: (2024-02-01)

Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia
by: Yi Wang, et al.
Published: (2025-04-01)

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
by: Maxime Jullien, et al.
Published: (2020-03-01)

Real-World Treatment Patterns, Clinical Outcomes, and Costs in Patients with Higher-Risk Myelodysplastic Syndromes Across France, Germany, and the United Kingdom
by: Drummond M, et al.
Published: (2025-06-01)

NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
by: Ying Lu, et al.
Published: (2024-09-01)

The Evolving Landscape of Myelodysplastic Syndrome Prognostication
by: Jacob Shreve, et al.
Published: (2020-04-01)

Factors affecting response and resistance to venetoclax in acute myeloid leukemia
by: Michael D. Diamantidis
Published: (2025-09-01)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
by: Mike-Andrew Westhoff, et al.
Published: (2022-01-01)